Vitamin D supplementation and COVID-19 risk: a population-based, cohort study
et al., Journal of Endocrinological Investigation, doi:10.1007/s40618-021-01639-9
, Vitamin D supplementation and COVID-19 risk: a population-based, cohort study, Journal of Endocrinological Investigation, doi:10.1007/s40618-021-01639-9
Retrospective study of cholecalciferol and calcitriol supplementation in Catalonia showing a small but significant lower risk of cases with cholecalciferol, but no significant difference for mortality, or for calcitriol supplementation. Significant benefit was found for cases, severity, and mortality in patients achieving serum vitamin D levels ≥30ng/ml.
|
risk of death, 1.0% higher, RR 1.01, p = 0.91, calcifediol, univariate.
|
|
risk of death, 4.0% lower, RR 0.96, p = 0.37, cholecalciferol, univariate.
|
|
risk of case, 1.0% lower, RR 0.99, p = 0.65, NNT 3499, calcifediol, univariate.
|
|
risk of case, 5.0% lower, RR 0.95, p = 0.004, cholecalciferol, multivariate.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
Oristrell et al., 17 Jul 2021, retrospective, population-based cohort, Spain, peer-reviewed, 8 authors, dosage varies (calcifediol).
Loading..
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation. FLCCC and WCH
provide treatment protocols.